HTH
- Company typePrivate
- Founded2020
- HeadquartersMilano, Italy
- Headcount1–10
- GTM typeB2B
- OfferingServices
HTH firmographics
Firmographics- Name
- HTH
- Website
- https://hthvc.com
- Company type
- Private
- Founded year
- 2020
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
HTH industry classification
Industry- Product category
- Venture Capital
- NAICS
- Other Financial Investment Activities (5239), Funds, Trusts, and Other Financial Vehicles (525), Management of Companies and Enterprises (55111)
- SIC
- Investors, Nec (6799)
- akta.pro primary industry
- Healthcare & Life Sciences Growth Equity (FSANACAB)
- akta.pro secondary industry
- Small-Cap Equity (Active) (FSAAAIAC)
Keywords
Where HTH is headquartered
LocationHeadquarters
- HQ city
- Milano
- HQ country
- Italy
- HQ region
- Europe
Markets served
HTH business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Others
HTH product offering
Product offeringCore offering
HTH is described as a Life Science Investment Company, indicating that its fundamental activity is providing capital and investment support to companies in the life sciences sector. Founded in 2020 and based in Milano, Italy, the firm is a small (1-10 employee) private investment vehicle led by a single Managing Principal and Founder. The public website (hthvc.com) did not render substantive content during data collection, so specific fund vehicles, ticket sizes, and portfolio composition could not be evidenced.
Differentiator
Problem solved
Functional benefit
Companies that use HTH
Customer profileIdeal customer profiles1 record
HTH technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
HTH partnerships and signals
Strategic signalRecent moves1 record
HTH competitors and assessment
Company assessmentDirect peers
- Sofinnova Partners: One of Europe's largest and longest-tenured life sciences venture capital firms, investing across biotech, medtech, and digital health from early to late stage. Directly comparable as a European-based life sciences-dedicated investment firm.
- EQT Life Sciences: European life sciences venture capital arm of EQT, investing across biotech, medtech, and digital health across Europe and the US. Comparable as a large, dedicated life sciences investor operating across European geographies.
- HealthCap: Nordic-based venture capital firm investing exclusively in life sciences, with a long-established track record across biotech and medtech in Europe. Comparable as a long-tenured European life sciences specialist investor.
- Atlas Venture: US- and UK-based early-stage life sciences venture capital firm that builds biotech companies from inception. Comparable as a specialist life sciences fund manager with a founder-led, early-stage orientation.
- Forbion: Leading European life sciences venture capital firm managing multi-billion-euro AUM across multiple funds, focused on therapeutics and life sciences companies. Directly comparable as a pan-European life sciences specialist investor.
- LSP (Life Sciences Partners): Amsterdam-based life sciences-focused investment firm managing public and private funds across European biotech and medtech. Comparable as a dedicated European life sciences investor.
- BioGeneration Ventures: Dutch-based venture capital firm dedicated to early-stage European biotech, with a long track record of building life sciences companies from inception. Comparable as a specialist European life sciences investor.
- Panakes Partners: Italian venture capital firm focused on life sciences — medical devices, biotech, and diagnostics — investing in early-stage European companies. Highly comparable given its Italy base and life sciences focus.
- Indaco Venture Partners: Italian venture capital manager with significant life sciences and healthcare exposure across multiple funds, investing from seed to growth. Directly comparable as an Italy-based VC with a life sciences focus.
Broad incumbents
- GIMV: Large Belgian-listed investment company with a substantial life sciences and health portfolio alongside broader technology and consumer investments. Comparable as an established European investor with significant life sciences exposure.
Market position
Strengths4 records
Weaknesses4 records
Key risks5 records
Key highlights4 records
Customer concentration
HTH social profiles
Digital presenceHTH financial estimates
Financial estimateRevenue estimate
Valuation estimate
HTH leadership team
Management profileNumber of profiles
Profiles1 record
HTH funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HTH M&A and investment
M&A and investmentM&A
Investments8 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HTH
What does HTH do?
HTH is described as a Life Science Investment Company, indicating that its fundamental activity is providing capital and investment support to companies in the life sciences sector. Founded in 2020 and based in Milano, Italy, the firm is a small (1-10 employee) private investment vehicle led by a single Managing Principal and Founder. The public website (hthvc.com) did not render substantive content during data collection, so specific fund vehicles, ticket sizes, and portfolio composition could not be evidenced.
When was HTH founded?
HTH was founded in 2020. It employs 1 to 10 people.
Where is HTH based?
HTH is headquartered in Milano, Italy, in the Europe region.
Who are HTH's main competitors?
Direct peers on record are Sofinnova Partners, EQT Life Sciences, HealthCap, Atlas Venture, Forbion, LSP (Life Sciences Partners), BioGeneration Ventures, Panakes Partners and Indaco Venture Partners. GIMV is listed as a broad incumbent.
Does HTH have an API?
No public API is recorded for HTH.
What industry is HTH in?
HTH's product category is Venture Capital. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity, with a secondary code of FSAAAIAC, Small-Cap Equity (Active). Its NAICS code is 5239 and its SIC code is 6799.